Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 years

被引：0
|
作者：
Lisi M. Dredze
Michael Friger
Samuel Ariad
Michael Koretz
Bertha Delgado
Ruthy Shaco-Levy
Margarita Tokar
Michael Bayme
Ravit Agassi
Maia Rosenthal
Victor Dyomin
Olga Belochitski
Shai Libson
Tamar Mizrahi
David B. Geffen
机构：
[1] Ben-Gurion University of the Negev,Faculty of Health Sciences
[2] Soroka University Medical Center,Department of Oncology
[3] Ben-Gurion University of the Negev,Department of Public Health
[4] Soroka Medical Center,Division of Surgery and The Eshkol Breast Center
[5] Soroka University Medical Center,Department of Pathology
[6] Soroka Medical Center,Department of Imaging and The Eshkol Breast Center
来源：
Breast Cancer Research and Treatment | 2022年 / 193卷
关键词：
Neoadjuvant; Doxorubicin-cyclophosphamide; Paclitaxel; Breast cancer; Real-world;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：597 / 612
页数：15
相关论文
共 16 条
  • [1] Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a median follow-up of 9.5 years
    Dredze, Lisi M.
    Friger, Michael
    Ariad, Samuel
    Koretz, Michael
    Delgado, Bertha
    Shaco-Levy, Ruthy
    Tokar, Margarita
    Bayme, Michael
    Agassi, Ravit
    Rosenthal, Maia
    Dyomin, Victor
    Belochitski, Olga
    Libson, Shai
    Mizrahi, Tamar
    Geffen, David B.
    BREAST CANCER RESEARCH AND TREATMENT, 2022, 193 (03) : 597 - 612
  • [2] Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience
    Singh, Jasmeet C.
    Mamtani, Anita
    Barrio, Andrea
    Morrow, Monica
    Sugarman, Steven
    Jones, Lee W.
    Yu, Anthony F.
    Argolo, Daniel
    Smyth, Lilian M.
    Modi, Shanu
    Schweber, Sarah
    Boafo, Camilla
    Patil, Sujata
    Norton, Larry
    Baselga, Jose
    Hudis, Clifford A.
    Dang, Chau
    ONCOLOGIST, 2017, 22 (02) : 139 - 143
  • [3] Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)
    G. G. Kimmick
    C. Cirrincione
    D. B. Duggan
    K. Bhalla
    N. Robert
    D. Berry
    L. Norton
    S. Lemke
    I. C. Henderson
    C. Hudis
    E. Winer
    Breast Cancer Research and Treatment, 2009, 113 : 479 - 490
  • [4] Sentinel node biopsy for axillary management after neoadjuvant therapy for breast cancer: a single-center retrospective analysis with long follow-up
    Ogawa, Yoshinari
    Ikeda, Katsumi
    Watanabe, Chika
    Kamei, Yuri
    Tokunaga, Shinya
    Tsuboguchi, Yuko
    Inoue, Takeshi
    Fukushima, Hiroko
    Ichiki, Makoto
    SURGERY TODAY, 2018, 48 (01) : 87 - 94
  • [5] Fifteen-year median follow-up results after neoadjuvant doxorubicin, followed by mastectomy, followed by adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) followed by radiation for stage III breast cancer: a phase II trial (CALGB 8944)
    Kimmick, G. G.
    Cirrincione, C.
    Duggan, D. B.
    Bhalla, K.
    Robert, N.
    Berry, D.
    Norton, L.
    Lemke, S.
    Henderson, I. C.
    Hudis, C.
    Winer, E.
    BREAST CANCER RESEARCH AND TREATMENT, 2009, 113 (03) : 479 - 490
  • [6] Sentinel node biopsy for axillary management after neoadjuvant therapy for breast cancer: a single-center retrospective analysis with long follow-up
    Yoshinari Ogawa
    Katsumi Ikeda
    Chika Watanabe
    Yuri Kamei
    Shinya Tokunaga
    Yuko Tsuboguchi
    Takeshi Inoue
    Hiroko Fukushima
    Makoto Ichiki
    Surgery Today, 2018, 48 : 87 - 94
  • [7] Neoadjuvant Chemotherapy with Docetaxel, Carboplatin and Weekly Trastuzumab Is Active in HER2-Positive Early Breast Cancer: Results after a Median Follow-Up of over 4 Years
    Kolberg, Hans-Christian
    Akpolat-Basci, Leyla
    Stephanou, Miltiades
    Aktas, Bahriye
    Hannig, Carla Verena
    Liedtke, Cornelia
    BREAST CARE, 2016, 11 (05) : 323 - 327
  • [8] Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up)
    Icli, Fikri
    Akbulut, Hakan
    Onur, Handan
    Yalcin, Bulent
    Demirkazik, Ahmet
    Senler, Filiz Cay
    BREAST, 2011, 20 (02) : 155 - 157
  • [9] Dose-escalation of filgrastim does not improve efficacy: Clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel
    Liu, Minetta C.
    Demetri, George D.
    Berry, Donald A.
    Norton, Larry
    Broadwater, Gloria
    Robert, Nicholas J.
    Duggan, David
    Hayes, Daniel F.
    Henderson, I. Craig
    Lyss, Alan
    Hopkins, Judith
    Kaufman, Peter A.
    Marcom, P. Kelly
    Younger, Jerry
    Lin, Nancy
    Tkaczuk, Katherine
    Winer, Eric P.
    Hudis, Clifford A.
    CANCER TREATMENT REVIEWS, 2008, 34 (03) : 223 - 230
  • [10] Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer
    Schneeweiss, Andreas
    Michel, Laura L.
    Moebus, Volker
    Tesch, Hans
    Klare, Peter
    Hahnen, Eric
    Denkert, Carsten
    Kast, Karin
    Pohl-Rescigno, Esther
    Hanusch, Claus
    Link, Theresa
    Untch, Michael
    Jackisch, Christian
    Blohmer, Jens-Uwe
    Fasching, Peter A.
    Solbach, Christine
    Schmutzler, Rita K.
    Huober, Jens
    Rhiem, Kerstin
    Nekljudova, Valentina
    Luebbe, Kristina
    Loibl, Sibylle
    EUROPEAN JOURNAL OF CANCER, 2022, 160 : 100 - 111
12